BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32327389)

  • 1. Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosis.
    Colomba J; Rabasa-Lhoret R; Bonhoure A; Bergeron C; Boudreau V; Tremblay F; Senior P; Potter K
    J Cyst Fibros; 2020 Sep; 19(5):704-711. PubMed ID: 32327389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of continuous glucose monitoring in screening for diabetes in cystic fibrosis].
    Khammar A; Stremler N; Dubus JC; Gross G; Sarles J; Reynaud R
    Arch Pediatr; 2009 Dec; 16(12):1540-6. PubMed ID: 19854630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MARKEDLY DELAYED INSULIN SECRETION AND A HIGH RATE OF UNDETECTED OVERT DIABETES CHARACTERIZE GLUCOSE METABOLISM IN ADULT PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATION.
    Winhofer Y; Wolf P; Fellinger P; Tura A; Hillebrand P; Staufer K; Trauner M; Jaksch P; Muraközy G; Kautzky-Willer A; Pacini G; Krebs M; Luger A; Kazemi-Shirazi L
    Endocr Pract; 2019 Mar; 25(3):254-262. PubMed ID: 30913015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report.
    Piechowiak K; Trippenbach-Dulska H; Walicka-Serzysko K
    Dev Period Med; 2015; 19(1):80-91. PubMed ID: 26003073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?
    Mainguy C; Bellon G; Delaup V; Ginoux T; Kassai-Koupai B; Mazur S; Rabilloud M; Remontet L; Reix P
    J Pediatr Endocrinol Metab; 2017 Jan; 30(1):27-35. PubMed ID: 27977404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose intolerance in cystic fibrosis as a determinant of pulmonary function and clinical status.
    Lavie M; Fisher D; Vilozni D; Forschmidt R; Sarouk I; Kanety H; Hemi R; Efrati O; Modan-Moses D
    Diabetes Res Clin Pract; 2015 Dec; 110(3):276-84. PubMed ID: 26508676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of dyslipidemia in adults with cystic fibrosis.
    Rhodes B; Nash EF; Tullis E; Pencharz PB; Brotherwood M; Dupuis A; Stephenson A
    J Cyst Fibros; 2010 Jan; 9(1):24-8. PubMed ID: 19875344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients.
    Ishimo MC; Belson L; Ziai S; Levy E; Berthiaume Y; Coderre L; Rabasa-Lhoret R
    J Cyst Fibros; 2013 May; 12(3):271-6. PubMed ID: 23017500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of glucose intolerance in cystic fibrosis.
    Mohan K; Miller H; Dyce P; Grainger R; Hughes R; Vora J; Ledson M; Walshaw M
    Diabet Med; 2009 Jun; 26(6):582-8. PubMed ID: 19538232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test.
    Schmid K; Fink K; Holl RW; Hebestreit H; Ballmann M
    J Cyst Fibros; 2014 Jan; 13(1):80-5. PubMed ID: 23809507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients.
    Clemente León M; Bilbao Gassó L; Moreno-Galdó A; Campos Martorrell A; Gartner Tizzano S; Yeste Fernández D; Carrascosa Lezcano A
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):45-51. PubMed ID: 29137964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis related diabetes mellitus - diagnostic and management challenges.
    Lek N; Acerini CL
    Curr Diabetes Rev; 2010 Jan; 6(1):9-16. PubMed ID: 20034372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of insulin secretion indices in cystic fibrosis patients.
    Hammana I; Potvin S; Tardif A; Berthiaume Y; Coderre L; Rabasa-Lhoret R
    J Cyst Fibros; 2009 Dec; 8(6):378-81. PubMed ID: 19782008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis.
    Darukhanavala A; Van Dessel F; Ho J; Hansen M; Kremer T; Alfego D
    PLoS One; 2021; 16(4):e0250036. PubMed ID: 33882078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis.
    Tofé S; Moreno JC; Máiz L; Alonso M; Escobar H; Barrio R
    Eur J Endocrinol; 2005 Feb; 152(2):241-7. PubMed ID: 15745932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis.
    Hammana I; Malet A; Costa M; Brochiero E; Berthiaume Y; Potvin S; Chiasson JL; Coderre L; Rabasa-Lhoret R
    Diabetes Metab; 2007 Jun; 33(3):213-9. PubMed ID: 17418606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical importance of cystic fibrosis-related diabetes.
    Brennan AL; Geddes DM; Gyi KM; Baker EH
    J Cyst Fibros; 2004 Dec; 3(4):209-22. PubMed ID: 15698938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between body composition, leptin levels and glucose dysregulation in youth with cystic fibrosis.
    Granados A; Beach EA; Christiansen AJ; Patterson BW; Wallendorf M; Arbeláez AM
    J Cyst Fibros; 2021 Sep; 20(5):796-802. PubMed ID: 34183284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis.
    Moheet A; Moran A
    Pediatr Pulmonol; 2017 Nov; 52(S48):S37-S43. PubMed ID: 28714601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulinogenic index and early phase insulin secretion predict increased risk of worsening glucose tolerance and of cystic fibrosis-related diabetes.
    Potter KJ; Boudreau V; Bonhoure A; Tremblay F; Lavoie A; Carricart M; Senior PA; Rabasa-Lhoret R
    J Cyst Fibros; 2023 Jan; 22(1):50-58. PubMed ID: 36028423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.